Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Date:3/20/2009

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced updated clinical results from its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers. The principal investigator for the trial is Professor Hardev Pandha of the Royal Surrey County Hospital, U.K. The results were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009.

Twenty-four patients were treated in the trial, with 17 evaluable for response. Fifteen of the 17 evaluable patients experienced Stable Disease (SD) or better, including five patients who experienced minor and Partial Responses (PR), giving a clinical benefit rate (SD + PR + Complete Response (CR)) of 88%.

"Heavily pretreated patients are the most difficult to treat," said Dr. Karl Mettinger, Chief Medical Officer for Oncolytics. "It is very encouraging to observe such a robust response rate, including a significant objective tumour response in this group.

"In future, we plan to combine docetaxel with REOLYSIN(R) in patients with metastatic sarcoma," added Dr. Mettinger. "Both REOLYSIN(R) and docetaxel have been demonstrated to be active against sarcoma, and there is ample preclinical evidence demonstrating that the combination may be synergistic in this patient group."

The Phase I trial (REO 010) had two components. The first was an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously to patients with docetaxel every three weeks. In this portion of the trial, standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial included the enrolment of additional patients at the top dose of REOLYSIN(R) in com
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
2. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
3. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
4. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
8. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
9. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
10. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
11. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Calif., May 11 Apex Bioventures Acquisition Corporation (NYSE ... that it has received notice from NYSE Amex LLC ... the Company has been accepted by the Exchange and ... 11, 2009 to regain compliance with the continued listing ...
... deCODE genetics,(Nasdaq: DCGN ) today announced its ... A conference call to discuss these results and,recent developments ... May 12, at 8:00am Eastern Daylight Time/12 noon GMT/1pm ... Net loss for the quarter ended March 31, 2009 ...
... May 11 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... overview at the upcoming Deutsche Bank 2009 Health Care Conference ... the Intercontinental Hotel, Boston.The live and archived webcast of the ... the Idenix Investor Center at www.idenix.com . ...
Cached Biology Technology:Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2deCODE genetics Announces First Quarter 2009 Financial Results 2deCODE genetics Announces First Quarter 2009 Financial Results 3deCODE genetics Announces First Quarter 2009 Financial Results 4deCODE genetics Announces First Quarter 2009 Financial Results 5deCODE genetics Announces First Quarter 2009 Financial Results 6deCODE genetics Announces First Quarter 2009 Financial Results 7deCODE genetics Announces First Quarter 2009 Financial Results 8
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
(Date:4/22/2014)... RIVERSIDE, Calif. Inspired by the fist-like club ... by University of California, Riverside, in collaboration with University ... design structure for composite materials that is more impact ... , "The more we study the club of this ... improve so many things we use every day," said ...
(Date:4/22/2014)... American Societies for Experimental Biology (FASEB) has released ... how funding from the National Institutes of Health (NIH) ... Rico. "FASEB is pleased to make these factsheets available ... NIH to their state," said FASEB President, Margaret K. ... for biomedical research funding, investing $29.2 billion in ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... role of the Dicer. MicroRNAs are emerging as ... an RNaseIII enzyme, plays a role in the biogenesis ... activity to determine the developmental role of DICER by ... p. 696 of this issue, Maatouk et al. add ...
... new insight into how the cell,s vast array of ... lethally malfunctioning molecules without a system for proteins to ... Just as eyeglasses improve vision, a coat provides warmth ... set of proteins called ubiquitin-like proteins (UBLs) as accessories ...
... after being exposed to a specialized electrical field is ... a stage of cancer already invading other parts of ... process and found cells that expanded the most were ... spread beyond its point of origin. The technique allows ...
Cached Biology News:October 2008 Biology of Reproduction highlights 2St. Jude study gives new insights into how cells accessorize their proteins 2St. Jude study gives new insights into how cells accessorize their proteins 3Expanding cell girth indicates seriousness of breast cancer 2